Cargando…

Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists

PURPOSE: Demyelinizing neurological disease is a rare complication after treatment with tumor necrosis factor (TNF)α antagonists. We report on a case of multiple sclerosis after TNFα antagonist treatment and discuss its differential diagnosis. METHODS: This is an observational case study. RESULTS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruè, Claudia, Mariotti, Cesare, Rossiello, Ilaria, Saitta, Andrea, Giovannini, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965533/ https://www.ncbi.nlm.nih.gov/pubmed/27504093 http://dx.doi.org/10.1159/000447086

Ejemplares similares

A Case of Goldenhar Syndrome Associated with a New Retinal Presentation: Exudative Vitelliform Maculopathy
por: Bruè, Claudia, et al.
Publicado: (2015)

Epiretinal membrane surgery for combined hamartoma of the retina and retinal pigment epithelium: role of multimodal analysis
por: Bruè, Claudia, et al.
Publicado: (2013)

Pigmented Free-Floating Posterior Vitreous Cyst
por: Bruè, Claudia, et al.
Publicado: (2012)

Spontaneous Closure of a Fully Developed Macular Hole in a Severely Myopic Eye
por: Bruè, C., et al.
Publicado: (2014)

Juxtapapillary Retinal Capillary Hemangioma: New Therapeutic Strategies
por: Saitta, Andrea, et al.
Publicado: (2014)

Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists
por: Swart, Reinout M., et al.
Publicado: (2009)

Solar Retinopathy: A Multimodal Analysis
por: Bruè, Claudia, et al.
Publicado: (2013)

25-Gauge Vitrectomy Combined with Half-Fluence Photodynamic Therapy for the Treatment of Juxtapapillary Retinal Capillary Hemangioma: A Case Report
por: Mariotti, Cesare, et al.
Publicado: (2014)

Effects of a Tumor Necrosis Factor-α Antagonist on Experimentally Induced Rhinosinusitis
por: Kim, Dong-Hyun, et al.
Publicado: (2011)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Atypical Presentation of Antiphospholipid Syndrome: A Case Report
por: Mariotti, Cesare, et al.
Publicado: (2014)

Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease
por: Navarrete-Dechent, Cristián, et al.
Publicado: (2015)

Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
por: Kim, Byungsoo, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Tumor necrosis factor-α antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis
por: Kim, Ji-Hye, et al.
Publicado: (2017)

Release kinetics of tumor necrosis factor-α and interleukin-1 receptor antagonist in the equine whole blood
por: Rütten, Simon, et al.
Publicado: (2016)

The neuroprotective effects of Chalcones from Ashitaba on cuprizone‐induced demyelination via modulation of brain‐derived neurotrophic factor and tumor necrosis factor α
por: Rowhanirad, Soodeh, et al.
Publicado: (2023)

No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
por: Banse, Christopher, et al.
Publicado: (2013)

Role of Demyelination in the Persistence of Neurological and Mental Impairments after COVID-19
por: Khodanovich, Marina Y., et al.
Publicado: (2022)

Editorial: Demyelinating neurological syndromes: The role of autoimmunity
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2023)

Cortical Laminar Necrosis associated with Osmotic Demyelination Syndrome
por: Cho, A-Hyun, et al.
Publicado: (2005)

Infective endocarditis following tumor necrosis factor-α antagonist therapy for management of psoriatic erythroderma: a case report
por: Mizuno, Takuro, et al.
Publicado: (2017)

Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-α antagonist: A case study
por: Ling, Xin, et al.
Publicado: (2017)

Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study
por: Bruè, C, et al.
Publicado: (2016)

Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-α antagonists and healthy matched controls
por: Zardi, Enrico Maria, et al.
Publicado: (2018)

1728. A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists
por: Harris, Courtney, et al.
Publicado: (2019)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence
por: ZHAO, HONGJUN, et al.
Publicado: (2016)

Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor
por: Chey, Shin Yee, et al.
Publicado: (2022)

Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
por: Endo, S, et al.
Publicado: (2000)

Demyelinating Neurological Adverse Events following the Use of Anti-TNF-α Agents: A Double-Edged Sword
por: Gharib, Miral H., et al.
Publicado: (2022)

Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists
por: Wu, Chun-Ying, et al.
Publicado: (2016)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020)

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

CNS Demyelination with TNF-α Blockers
por: Kemanetzoglou, Elissavet, et al.
Publicado: (2017)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Salivary tumor necrosis factor-α and periodontal destruction
por: Tin, Sim Sai, et al.
Publicado: (2015)

Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology
por: Salomon, Benoît L., et al.
Publicado: (2018)

Tumor necrosis factor α Inhibition for Alzheimer’s Disease
por: Chang, Rudy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6q31ol6rna4h2384m12aapkkh4